OSLO, Norway—NattoPharma ASA, in collaboration with Complementary Medicines Group (CMG) Australia, successfully entered into the Australian and New Zealand markets.

This collaboration has resulted in several developments. First, Blackmores, Australia’s leading natural health brand, will utilize NattoPharma’s MenaQ7® Vitamin K2 in a soon-to-be released that will sell both online and through brick-and-mortar stores across Australia. BioCeuticals, supplier of high-quality practitioner-specific nutritional and therapeutic supplements, has also signed on to use its MenaQ7 Vitamin K2 in an upcoming product.

In addition, another new product concept has already been released: Essential Nutrition Vitamin K2, a standalone bone health product featuring MenaQ7 Vitamin K2 as MK-7.

“Bone health is a serious concern, and the introduction of MenaQ7 Vitamin K2 to the Australian and New Zealand markets has been significant," said Craig Fallshaw, CMG founder. “It is so validating to bring the only clinically validated, patented vitamin K2 as MK-7 to these markets."

NattoPharma also recently expanded and strengthened its patent application for MenaQ7® in the United States.